Lupin Partners with Spain's ERN to Launch Luforbec for Asthma and COPD Treatment
Mumbai: Global pharma major Lupin Limited (Lupin) has announced its strategic collaboration with LABORATORIOS ERN S.A. (ERN), a well-established Spanish pharmaceutical company, for the launch of Luforbec (beclometasone/formoterol) 100/6, a fixed dose combination in a pressurized metered dose inhaler, for the treatment of adult asthma and chronic obstructive pulmonary disease, in Spain.
This collaboration combines Lupin’s global respiratory expertise and proven pMDI manufacturing excellence and ERN’s robust national reach and deep customer relationships, marking an exciting milestone in expanding high-quality respiratory care to patients across Spain.
Thierry Volle, President EMEA and Emerging Markets, Lupin said, “The launch of Luforbec® in Spain, following successful introductions in the UK and Germany, represents a key milestone in our partnership with ERN and reinforces our commitment to advancing global access to quality respiratory care. Together, we are building something truly exciting for patients and healthcare professionals.”
“Partnering with Lupin allows us to bring a proven, high‑value respiratory therapy to Spanish patients and healthcare professionals. It represents an opportunity for ERN to expand into a new therapeutic area,” said David Solanes, CEO of LABORATORIOS ERN, S.A.
Luforbec® is indicated for the regular treatment of asthma where the use of a combination product (inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) is appropriate. This includes patients not adequately controlled with ICS and ‘as needed’ inhaled short-acting beta2-agonist or patients already adequately controlled on both ICS and LABA. Luforbec® is also indicated in the symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
LABORATORIOS ERN S.A. is a Spanish pharmaceutical company with headquarters in Barcelona. The company currently manufactures more than 28 million units per year and commercializes a portfolio of over 35 active pharmaceutical ingredients in Spain.
The firm is committed to providing healthcare professionals and patients with high-quality branded generic medicines at affordable prices, as well as self-care products. The company is highly specialized in paediatrics, offering innovative medicines designed to improve clinical effectiveness, tolerability, safety, and treatment adherence, with the goal of enhancing the quality of life of the paediatric population.
It continuously works to optimize the cost–benefit ratio of its medicines, supporting the sustainability of the healthcare system. The company has successfully adapted to a dynamic and evolving environment shaped by technological advances, changing healthcare needs, and increasing market competition. Its purpose is to remain true to this model by ensuring the continued availability of critical and essential medicines for the national healthcare system, thereby contributing to sustainable improvements in people’s quality of life.
